Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy

Summary

A randomized controlled trial comparing the effect of local ablative MR-guided radiotherapy (MRgRT) after systemic therapy with current standard treatment alone, on health-related quality of life in patients with locally advanced pancreatic cancer (LAPC).

Interventions

• MR guided radiotherapy · RADIATION

  5 fractions of 10 Gray MRgRT in addition to standard of care

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Pathology proven pancreatic ductal adenocarcinoma (PDAC);
* At least two (preferably four) months systemic therapy with (m)FOLFIRINOX and/or gemcitabine + nab-paclitaxel; or eligibility for chemotherapy but no initiation of chemotherapy based on patients' wish;
* No option for surgical resection, either because anatomical irresectability based on the surgeon's judgement (assessed on imaging or during explorative laparotomy) and/or frailty (unfit for surgery or chemotherapy) and/or no surgery based on patient's wish.
* No evidence of distant metastatic disease progression, evaluated by CT Thorax / Abdomen / Pelvis and/or PET-CT scan;
* Performance status WHO 0-2.

Exclusion Criteria:

* Contra-indications for MRI or CT with an intravenous contrast agent according to the protocol of the local radiology and/or radiotherapy departments

  * Contraindications for MRgRT, as determined by the involved expert radiation oncologists of the Consortium
  * \<18 years old
  * Pregnancy

Sites (4)

• Catharina Hospital, Eindhoven, North Brabant, Netherlands
• Amsterdam University Medical Center, VUmc, Amsterdam, North Holland, Netherlands
• Radboud University Medical Center, Nijmegen, Netherlands
• University Medical Center Utrecht, Utrecht, Netherlands